- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02685618
Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA)
Safety and Efficacy of Low-dose Prostacyclin Administration and Blood Pressure Target in Addition to Standard Therapy, as Compared to Standard Therapy Alone, in Post-cardiac-arrest-syndrome Patients - a Randomized, Controlled, Double-blinded Investigator-initiated Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Trial Rationale: Therapeutic interventions directed towards the damaged endothelium may improve outcome for patients with PCAS. Prostacyclin/Iloprost (PGI2) is an endogenous prostanoid which is formed and released by endothelial cells with anti-platelet, vasodilatory and cytoprotective properties36 and is expected to be beneficial by protecting and deactivating the endothelium and by restoring vascular integrity in patients suffering from endothelial breakdown.
Trial Population: Participants in the trial must be adult patients (≥18 years of age) with out-of-hospital cardiac arrest (OHCA) of presumed cardiac cause admitted to the Dept. of Cardiology, 2143, Rigshospitalet, Copenhagen.
Trial Design: Randomized, placebo controlled, double-blind investigator-initiated trial in 40 OHCA patients. 48 hours of active study drug (Iloprost, 1 ng/kg/min) versus placebo (saline) infusion.
Patients in both randomization groups will be treated in accordance with state-of-the art therapy including targeted temperature management. Interventions are considered emergency procedures and study drug infusion should be commenced as soon as possible after sustained return of spontaneous circulation (ROSC), screening and randomization.
Patients will only be enrolled after informed consent, but as the treatment has to be initiated earliest possible after the out of hospital cardiac arrest diagnosis i.e., at a time-point where patients are temporarily incompetent, scientific guardians will co-sign the informed consent form before inclusion. Next-of-kin and the patients' general practitioner will co-sign as soon as possible and the patient will provide informed consent whenever possible.
During the study, blood samples will be taken at different time points. Patients will be observed and assessed continuously with regards to complications including bleeding. Patients will be actively assessed as long as the patient is in the ICU. During the extended follow up period at day 30, 90 and 180 contact will be made with the patients to follow up on safety events and vital status.
The trial is conducted in accordance with the protocol and is approved by Danish health and medicines authority, Danish ethics committee and danish data protection agency.
Investigational product: The active treatment in the trial is 1 ng/kg/min Ilomedin® administered as a 48h continuous i.v infusion. The drugs will be administered according to the product specifications.
Placebo: The placebo is 0.9% saline administered as a 48h continuous i.v infusion. The i.v volume of placebo saline to be administered is equal to the administered volume of diluted (in 0.9% saline) active drug.
Sponsor of study and financial support: This research project is investigator-initiated by the trial Sponsor Pär I. Johansson in collaboration with the principal investigator Christian Hassager.
It has not received funding from any commercial sponsors.
Patient recruitment period runs from February 2016 to August 2016. Follow-up data on 30-day, 90-day and 180-day outcome and adverse events will be collected. Initial data analyses will be done after completion of 30-day follow-up for all patients. Secondary data analyses will be done after completion of 180-day follow-up for all patients.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Copenhagen, Denmark, DK-2100
- Dept. of Cardiology, 2143, Rigshospitalet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥18 years
- OHCA of presumed cardiac cause
- Sustained ROSC*
- Unconsciousness (GCS <8) (patients not able to obey verbal commands) after sustained ROSC*
- Target temperature management is indicated.
Exclusion Criteria:
- Conscious patients (obeying verbal commands)
- Females of childbearing potential (unless a negative human chorionic gonadotropin (HCG) test can rule out pregnancy within the inclusion window)
- Patients weighing more than 135kg
- In-hospital cardiac arrest (IHCA)
- OHCA of presumed non-cardiac cause, e.g. after trauma or dissection/rupture of major artery OR Cardiac arrest caused by initial hypoxia (i.e. drowning, suffocation, hanging).
- Known congenital bleeding diathesis (medically induced coagulopathy due to treatment with Vitamin K antagonists, Thrombininhibitors, Factor Xa inihbitors, ADP-receptor inhibitors, Aspirin, Asasantin, Persantin, NSAID, unfractionated and low molecular weight heparin does NOT exclude the patient).
- Suspected or confirmed acute intracranial bleeding
- Suspected or confirmed acute stroke
- Unwitnessed asystole
- Known limitations in therapy and Do Not Resuscitate-order
- Known disease making 180 days survival unlikely
- Known pre-arrest CPC 3 or 4
- >4 hours (240 minutes) from ROSC to screening
- Systolic blood pressure <80 mm Hg in spite of fluid loading/vasopressor and/or inotropic medication/intra-aortic balloon pump/axial flow device*
- Temperature on admission <30°C.
- Known allergy to Prostacyclin analogues
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Iloprost + M1006B offset by -10 mmHg
Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg Intervention: Drug: Iloprost + M1006B offset -10mmHg |
Other Names:
Administration of blood pressure module M1006B: offset by -10 mmHg
|
Experimental: Iloprost + M1006B, No offset
Administration of 1 ng/kg/min Ilomedin® as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset Intervention: Drug: Iloprost + M1006B, No offset |
Other Names:
Administration of blood pressure module M1006B: No offset
|
Placebo Comparator: Placebo + M1006B offset by -10 mmHg
Double dummy 0.9% saline as a 48h continuous i.v infusion. Administration of blood pressure modules M1006B: offset by -10 mmHg Intervention: Drug: Placebo + M1006B offset -10mmHg |
Other Names:
Administration of blood pressure module M1006B: offset by -10 mmHg
|
Placebo Comparator: Placebo + M1006B, No offset
Double dummy 0.9% saline as a 48h continuous i.v infusion Administration of blood pressure modules M1006B: No offset Intervention: Drug: Placebo + M1006B, No offset |
Other Names:
Administration of blood pressure module M1006B: No offset
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change i plasma biomarkers reflecting endothelial activation and damage
Time Frame: 48 hours
|
Mean change in biomarkers indicative of endothelial activation and damage (sE-selectin, syndecan-1, soluble thrombomodulin (sTM), soluble vascular endothelial growth factor (sVEGF), nucleosomes) and sympathoadrenal overactivation (epinephrine/norepinephrine) from baseline to 48 hours post-randomization.
|
48 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in hemostatic profile evaluated by TEG, Multiplate, Flowcytometry
Time Frame: 48 hours
|
Mean change in the hemostatic profile evaluated by Thrombelastography (TEG)(change in functional hemostatic blood test) and Multiplate (whole blood platelet aggregometry) and change in Flowcytometry (change in blood cell and endothelial cell derived microparticles).
from baseline to 48 hours post-randomization.
|
48 hours
|
Blood pressure target influence on primary outcomes measured by mean change in plasma biomarkers.
Time Frame: 48 hours
|
Blood pressure target (65 mmHg or 75 mmHg) influence on the endothelial response to the study drug (mean change in biomarkers reflecting endothelial activation and damage) and change in levels of Neuron Specific Enolasis from baseline to 48 hours post-randomization.
|
48 hours
|
Feasibility of blood pressure target intervention.
Time Frame: 48 hours
|
Feasibility of blood pressure target intervention .(Target
90%)
|
48 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with severe bleeding
Time Frame: 24 hours-180 days
|
Severe bleeding (intracranial or clinical bleeding with the use of 3 red blood cells (RBC) units or more/24 hours)
|
24 hours-180 days
|
Number of patients requiring organ support
Time Frame: 48 hours to 180 days
|
Days of vasopressor, ventilator and renal replacement therapy post-randomization.
|
48 hours to 180 days
|
Mean change in disease severity score
Time Frame: 48 to 96 hours
|
Changes in SOFA score from baseline to 48 h and day 4 post-randomization.
|
48 to 96 hours
|
Number of patients with transfusion requirements
Time Frame: 48 hours to 180 days
|
Use of blood products (in ICU) post-randomization.
|
48 hours to 180 days
|
Grading of Neurological function.
Time Frame: to 180 days
|
Neurological function graded by modified Rankin Scale (mRS) and Cerebral Performance Category (CPC) at 180 days.
|
to 180 days
|
Mortality
Time Frame: 24 hours to 180 days
|
Difference in day 7, 30, 90 and 180 day mortality between patients receiving active treatment (lloprost) and placebo.
|
24 hours to 180 days
|
Evaluation of Renal function
Time Frame: 24 to 96hours
|
Estimated glomerular filtration rate (eGFR) and urine output at day 2 and 3 and need for renal replacement therapy.
|
24 to 96hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chistian Hassager, MD, DMSc, Dept. of Cardiology, 2143, Rigshospitalet, Blegdamsvej 0, DK-2100
Publications and helpful links
General Publications
- Meyer ASP, Ostrowski SR, Kjaergaard J, Frydland M, Thomsen JH, Johansson PI, Hassager C. Low dose Iloprost effect on platelet aggregation in comatose out-of-hospital cardiac arrest patients: A predefined sub-study of the ENDO-RCA randomized -phase 2- trial. J Crit Care. 2020 Apr;56:197-202. doi: 10.1016/j.jcrc.2019.12.025. Epub 2019 Dec 30.
- Meyer ASP, Johansson PI, Kjaergaard J, Frydland M, Meyer MAS, Henriksen HH, Thomsen JH, Wiberg SC, Hassager C, Ostrowski SR. "Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA): Safety and efficacy of low-dose Iloprost, a prostacyclin analogue, in addition to standard therapy, as compared to standard therapy alone, in post-cardiac-arrest-syndrome patients.". Am Heart J. 2020 Jan;219:9-20. doi: 10.1016/j.ahj.2019.10.002. Epub 2019 Oct 21.
- Meyer AS, Ostrowski SR, Kjaergaard J, Johansson PI, Hassager C. Endothelial Dysfunction in Resuscitated Cardiac Arrest (ENDO-RCA): safety and efficacy of low-dose prostacyclin administration and blood pressure target in addition to standard therapy, as compared to standard therapy alone, in post-cardiac arrest syndrome patients: study protocol for a randomized controlled trial. Trials. 2016 Aug 2;17:378. doi: 10.1186/s13063-016-1477-z.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014092629
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Arrest
-
Australian and New Zealand Intensive Care Research...Ambulance VictoriaNot yet recruitingOut of Hospital Cardiac Arrest
-
University Medical Centre MariborRecruiting
-
IRCCS Policlinico S. MatteoOslo University Hospital; University of the Basque Country (UPV/EHU); The Hospital...CompletedOut-Of-Hospital Cardiac ArrestItaly, Norway, Spain
-
Lithuanian University of Health SciencesEgle Vaitkaitiene; Dinas Vaitkaitis; Asta Krikscionaitiene; Ilona Kajokaite; Nerijus...CompletedOut-Of-Hospital Cardiac ArrestLithuania
-
Ceric SàrlAbbottTerminatedOut of Hospital Cardiac ArrestBelgium, France, Serbia
-
Prehospital Center, Region ZealandCompletedOut-Of-Hospital Cardiac Arrest
-
Karolinska InstitutetSwedish Heart Lung FoundationCompletedCardiac Arrest | Out of Hospital Cardiac ArrestSweden
-
Karolinska InstitutetVastra Gotaland Region; SOS Alarm Sverige AB; Everdrone AB; Aviation capacity resources... and other collaboratorsCompleted
-
Brno University HospitalTerminatedOut-Of-Hospital Cardiac ArrestCzechia
-
SRINIVAS RAMAKAUnknownOut-Of-Hospital Cardiac ArrestIndia
Clinical Trials on Saline
-
Vanderbilt University Medical CenterActive, not recruitingPostural Tachycardia SyndromeUnited States
-
Johns Hopkins UniversityCystic Fibrosis FoundationCompletedCystic Fibrosis
-
University Hospital Inselspital, BerneCompletedCardiovascular Diseases | Valvular Heart DiseaseSwitzerland
-
Imam Abdulrahman Bin Faisal UniversityUnknownOtorhinolaryngologic Diseases | RhinosinusitisSaudi Arabia
-
Aalborg UniversityThe Danish Rheumatism AssociationCompleted
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia
-
Dr. Michael FlavinWithdrawn
-
Szpital im. Św. Jadwigi ŚląskiejRecruiting
-
Makassed General HospitalCompletedLength of Hospital StayLebanon
-
University of Washington, the Collaborative Health...Cystic Fibrosis FoundationCompleted